
LSP leads €21m round into Neurent Medical
Galway-based medical device company Neurent Medical, which is focussed on chronic inflammatory diseases of the sinuses and nasal passages said it...

AZD1222 claims 79% effecacy in pivotal US study
For exactly one day, the belief that AstraZeneca's COVID-19 vaccine AZD1222 may be better than its reputation lasted. But because the ailing vaccine...

Step Pharma SAS raises €35m in Series B
The financing round of the French drug development company was co-led by new investors Hadean Ventures and Sunstone Life Science Ventures with...

miRNAs unmask vulnerability in breast cancer stem cells
The study results, published in the Journal of Cell Biology, reveal that targeting these microRNAs sensitivies cancer stem cells to certain...

EU orders additional COVID-19 vaccine doses
Under the new deal, the Commission has the option to request supply of an additional 100 million doses. This new agreement is in addition to the 300...

Roche Phase III study misses COVID-19 endpoint
In the Phase III REMDACTA trial, the Swiss pharma major combined its cytokine storm blocker tocolizumab with Gilead Science’s viral transcription...

EMA: AZD1222 causes serious rare ADEs
However, the EMA has no idea which component of the cheapest COVID-19 vaccine on the market is supposed to cause the splanchnic leg and sinus vein...